Obesema 2.4mg Injection
Available Pack Sizes
Free Shipping
Order above $200.00
Worldwide Delivery
8-10 Business Days
24/7 Support
Solve your queries
- 100% Genuine Medicines
- Secure International Logistics
- Secure Payment
- Authentic Pharmaceutical Supplier
How to Order from Medionix Pharma
Add Products
Browse our medicines and add the required products to your cart.
Add Products to Cart
Order Method
Place your order easily through WhatsApp or Email support.
Choose Your Ordering Method
Share Details
Provide your delivery address and contact information.
Share Delivery & Prescription Details
Order Dispatched
Your order is packed securely and shipped worldwide.
Order Confirmation & Dispatch
Obesema 2.4mg Injection
contains Semaglutide 2.4mg per weekly dose in a pre-filled pen, manufactured by Abbott. This is the maximum approved dose of semaglutide for chronic weight management, delivering the landmark ~15% average body weight reduction demonstrated in the STEP clinical trials — now accessible at an affordable Abbott India price. It is the direct equivalent of Wegovy 2.4mg.
Benefits:
- ~15% average body weight reduction over 68 weeks (STEP-1 trial)
- 20% reduction in major cardiovascular events in overweight adults (SELECT trial)
- Maximum GLP-1 receptor activation for superior appetite suppression and satiety
- Long-term maintenance dose — sustainable indefinitely as directed by prescriber
- Manufactured by Abbott — India's globally recognised pharmaceutical leader
How It Works:
At the 2.4mg maximum dose, semaglutide achieves full GLP-1 receptor saturation, producing the most powerful available appetite suppression, maximum gastric emptying delay, and near-complete glucose-dependent insulin stimulation. This combination drives the ~15% body weight reduction across 68 weeks observed in STEP trials, with continued weight maintenance during long-term use.
Dosage and Administration:
Inject 2.4mg subcutaneously once weekly at any time of day with or without food. Use the abdomen, thigh, or outer upper arm. Rotate injection sites. This is the long-term maintenance dose — continue indefinitely as directed by your prescriber.
Side Effects:
Common: nausea, diarrhoea, vomiting, constipation, decreased appetite, abdominal pain. Uncommon: fatigue, dizziness, elevated resting heart rate. Serious: pancreatitis, gallbladder disease, acute kidney injury.
Precautions:
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Ensure adequate protein and micronutrient supplementation during significant weight loss. Monitor for gallbladder disease, mood changes, and dehydration. Not recommended in pregnancy.
Obesema Dosage Comparison Guide
| Strength | Best For | Onset | Duration | Link |
|---|---|---|---|---|
| 0.25mg | Lower strength option | 2–4 wks | Weekly | View → |
| 0.5mg | Standard strength option | 2–4 wks | Weekly | View → |
| 1mg | Popular strength option | 2–4 wks | Weekly | View → |
| 1.7mg | Higher strength option | 2–4 wks | Weekly | View → |
| 2.4mg | Maximum strength variant | 2–4 wks | Weekly | Current |
* Always consult your doctor before changing your dosage. This information is for educational reference only.
Frequently Asked Questions
Q1: What is Obesema 2.4mg used for?
Obesema 2.4mg is the maximum maintenance dose of injectable semaglutide by Abbott, used for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, alongside a reduced-calorie diet and increased physical activity.
Q2: Is Obesema 2.4mg equivalent to Wegovy 2.4mg?
Yes. Obesema 2.4mg delivers the same semaglutide active ingredient at the same maximum dose as Wegovy. It achieves the same ~15% body weight reduction over 68 weeks at a substantially lower price due to Abbott India's generic manufacturing economics.
Q3: How long should I remain on Obesema 2.4mg?
Indefinitely, in most cases. Semaglutide is a long-term treatment analogous to antihypertensive therapy. Stopping typically leads to weight regain in the majority of patients. Annual review with your prescriber should assess ongoing benefit.
Q4: What cardiovascular benefit does Obesema 2.4mg offer?
The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in overweight/obese adults with established cardiovascular disease. Obesema 2.4mg, as the equivalent dose, is expected to confer the same benefit.
Q5: What monitoring is required on Obesema 2.4mg?
Regular body weight tracking, HbA1c (in diabetic patients), renal function, and liver enzymes annually. Gallbladder ultrasound if abdominal symptoms develop. Nutritional assessment for patients with very low food intake.
Customer Reviews
Dr. James Wilson
USA · 1 week ago
“Excellent product quality. Arrived well-packaged with proper cold chain maintained throughout transit. Will order again.”
Priya Sharma
India · 1 month ago
“Prompt response from the team and smooth ordering process. Medicine arrived in original sealed packaging as expected.”
FirstCare Clinic
Canada · 3 months ago
“Good value for bulk procurement orders. Communication was clear and the shipment arrived within the estimated timeframe.”
Dr. Maria Santos
Australia · 3 weeks ago
“Good quality product. Shipping was fast and handled with care. Would recommend for professional hospital procurement.”
Michael K.
USA · 2 months ago
“Fast international shipping and professional packaging. Product was exactly as described. Highly recommend this supplier.”
Related Products
Disclaimer
The information provided on Medionix Pharma is intended for general informational purposes only. It should not be considered as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or starting any treatment.
Medionix Pharma does not encourage self-medication. Customers are responsible for ensuring that purchases comply with local laws and prescription requirements in their country. If you have any questions or concerns regarding the content on our website, please contact us at sales@medionixpharma.com.